Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Natrunix vs Methotrexate in Rheumatoid Arthritis
NCT05363917Phase 2Unknown
- Sponsor
- XBiotech Inc.
- Start
- Jun 2022
- Primary completion
- Dec 2022
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, randomised, double-blind trial of XB2001 in rheumatoid arthritis (RA) (2 arms), sponsored by XBiotech Inc. Primary endpoint: American College of Rheumatology 50% Response at 12 weeks. Status: unknown.
02
Drugs
XB2001
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT05363917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05363917.